We provide you with 20 years of free, institutional-grade data for TSHA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TSHA. Explore the full financial landscape of TSHA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$963,903
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Nagendran Sukumar | Sale | -200,000 | $3.23 | $646,000 | 2025-09-12 |
| Nagendran Sukumar | Derivatives Exercise | 41,150 | 2025-09-12 | ||
| Nagendran Sukumar | Sale | -57,054 | $2.85 | $162,604 | 2025-08-22 |
| Alam Kamran | Sale | -54,491 | $2.85 | $155,299 | 2025-08-22 |
| Stalfort John A III | Grant, award...etc | 56,623 | 2025-06-04 | ||
| Donenberg Phillip B. | Grant, award...etc | 56,623 | 2025-06-04 | ||
| Sepp-Lorenzino Laura | Grant, award...etc | 56,623 | 2025-06-04 | ||
| Long Alison S | Grant, award...etc | 56,623 | 2025-06-04 | ||
| Manning Paul B | Open Market Purchase | 750,000 | $2.75 | 2025-06-03 | |
| Alam Kamran | Sale | -29,843 | $1.69 | $50,435 | 2025-03-13 |
| Alam Kamran | Grant, award...etc | 431,000 | 2025-01-03 | ||
| Nagendran Sukumar | Grant, award...etc | 324,500 | 2025-01-03 | ||
| Nolan Sean P. | Grant, award...etc | 892,500 | 2025-01-03 | ||
| Manning Paul B | Open Market Purchase | 1,333,333 | $2.25 | 2024-07-01 | |
| Long Alison S | Grant, award...etc | 49,220 | 2024-05-31 | ||
| Stalfort John A III | Grant, award...etc | 49,220 | 2024-05-31 | ||
| Sepp-Lorenzino Laura | Grant, award...etc | 49,220 | 2024-05-31 | ||
| Donenberg Phillip B. | Grant, award...etc | 49,220 | 2024-05-31 | ||
| Alam Kamran | Sale | -1,288 | $1.51 | $1,945 | 2024-02-06 |
| Nagendran Sukumar | Grant, award...etc | 863,617 | 2024-01-04 | ||
| Alam Kamran | Grant, award...etc | 590,413 | 2024-01-04 | ||
| Nolan Sean P. | Grant, award...etc | 1,184,688 | 2024-01-04 | ||
| Manning Paul B | Open Market Purchase | 100,000 | $1.63 | 2023-11-20 | |
| Alam Kamran | Sale | -33,000 | $2.33 | $76,890 | 2023-08-25 |
| Manning Paul B | Open Market Purchase | 16,466,667 | $0.9 | 2023-08-16 | |
| Stalfort John A III | Open Market Purchase | 388,889 | $0.9 | 2023-08-16 | |
| Stalfort John A III | Open Market Purchase | 388,889 | $0.9 | 2023-08-16 | |
| Nolan Sean P. | Open Market Purchase | 444,444 | $0.9 | 2023-08-16 | |
| Donenberg Phillip B. | Open Market Purchase | 111,111 | $0.9 | 2023-08-16 | |
| Session R.A. II | Sale | -85,872 | $0.71 | $60,815 | 2023-07-14 |
| Session R.A. II | Sale | -28,608 | $0.7 | $20,103 | 2023-06-26 |
| Stalfort John A III | Initial | 2023-06-26 | |||
| Session R.A. II | Sale | -434,615 | $0.71 | $309,011 | 2023-06-22 |
| Alam Kamran | Grant, award...etc | 6,230 | 2023-06-02 | ||
| Nagendran Sukumar | Open Market Purchase | 5,000 | $0.68 | 2023-05-18 | |
| Alam Kamran | Grant, award...etc | 18,691 | 2023-02-06 | ||
| Manning Paul B | Open Market Purchase | 1,500,000 | $2 | 2022-11-02 | |
| Audentes Therapeutics, Inc. | Initial | 2022-10-31 |
The information provided in this report about TSHA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Taysha Gene Therapies, Inc(NASDAQ:TSHA) 
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the t...
Website: http://www.tayshagtx.com
Founded: 2019
CEO: R. A. Session
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends